LPTX - リ―プ・セラピュ―ティクス （LEAP THERAPEUTICS INC.） リ―プ・セラピュ―ティクスLPTXのチャート
LPTXの企業情報
| symbol | LPTx |
|---|---|
| 会社名 | Leap Therapeutics Inc （リ―プ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Leap Therapeutics Inc. formerly HealthCare Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer cholangiocarcinoma non-small cell lung cancer and other tumor types such as pancreatic gastric liver head and neck uterine and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. . リ―プ・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、主に免疫療法によるがん治療の開発に従事する。がん細胞に発現しているタンパク質に対するモノクロナ―ル抗体に注目し、体内の免疫システムを起動させるメカニズムに取り組む。同社の臨床プログラムは「DKN-01」と「TRX518」である。本社はマサチュ―セッツ州ケンブリッジ。 Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. |
| 本社所在地 | 47 Thorndike Street Suite B1-1 Cambridge MA 02141 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 617-252-4343 |
| 設立年月日 | 40544 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 22人 |
| url | www.leaptx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/lptx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -28.26200 |
| 終値（lastsale） | 6.54 |
| 時価総額（marketcap） | 96142453.74 |
| 時価総額 | 時価総額（百万ドル） 95.99545 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 65.51445 |
| 当期純利益 | 当期純利益（百万ドル） -42.69400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Leap Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 9% to $18M. Higher net loss reflects Foreign currency gains (loss) decrease from $36K (income) to $366K (expense) Australian research and development ince decrease of less than 1% to $889K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.13 to -$1.35. |
LPTXのテクニカル分析
LPTXのニュース
FY2023 EPS Estimates for Leap Therapeutics, Inc. Cut by HC Wainwright (NASDAQ:LPTX) 2023/03/30 05:38:43 The AM Reporter
Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Rating) – Equities research analysts at HC Wainwright decreased their FY2023 EPS estimates for Leap Therapeutics in a research note issued on Monday, March 27th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.20) for the year, down from their prior […]
Leap Therapeutics GAAP EPS of -$0.11 in-line 2023/03/24 11:21:56 Seeking Alpha
Leap Therapeutics press release (LPTX): Q4 GAAP EPS of -$0.11 in-line.Cash and cash equivalents totaled $65.5 million at December 31, 2022, which excludes the approximately $50…
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results 2023/03/24 11:00:00 PR Newswire
CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022. Leap Highlights:…
BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics'' Lead Cancer Candidate 2023/03/17 14:26:21 Benzinga
Leap Therapeutics Inc (NASDAQ: LPTX ) announced BeiGene Ltd''s (NASDAQ: BGNE ) option under the Exclusive Option, and License Agreement granting rights in certain Asian territories to DKN-01 has expired . The companies announced an option agreement in January 2020 for DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Leap and BeiGene will continue collaborating on Part C of the DisTinGuish trial, a … Full story available on Benzinga.com
Morning Sizzling Stocks Alert: Greenidge Generation Holdings Inc. (NASDAQ:GREE), Leap Therapeutics, Inc. (NASDAQ:LPTX) 2023/02/23 04:34:35 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Morning Sizzling Stocks Alert: Greenidge Generation Holdings Inc. (NASDAQ:GREE), Leap Therapeutics, Inc. (NASDAQ:LPTX) appeared first on Stocks Equity .
What Can Leap Therapeutics Inc. (NASDAQ: LPTX) Expect In 2022? 2022/03/26 14:30:00 Stocks Register
Leap Therapeutics Inc. (NASDAQ:LPTX) price on Friday, March 25, fall -2.79% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.74. A look at the stock’s price movement, the close in the last trading session was $1.79, moving within a range at $1.71 and $1.795. The beta value … What Can Leap Therapeutics Inc. (NASDAQ: LPTX) Expect In 2022? Read More »
Leap Therapeutics: Q4 Earnings Insights 2022/03/11 12:50:37 Benzinga
Leap Therapeutics (NASDAQ: LPTX ) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Leap Therapeutics beat estimated earnings by 9.09%, reporting an EPS of … Full story available on Benzinga.com
Leap Therapeutics GAAP EPS of -$0.10 beats by $0.01, revenue of $0.38M beats by $0.08M 2022/03/11 12:33:14 Seeking Alpha
Leap Therapeutics press release (LPTX): Q4 GAAP EPS of -$0.10 beats by $0.01.Revenue of $0.38M (flat Y/Y) beats by $0.08M.CEO comment: "Following our public offering, we are well…
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results 2022/03/11 12:00:00 PR Newswire
CAMBRIDGE, Mass., March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2021. Leap Highlights:…
Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference 2022/03/02 12:00:00 PR Newswire
CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at…
What Can Leap Therapeutics Inc. (NASDAQ: LPTX) Expect In 2022? 2022/03/26 14:30:00 Stocks Register
Leap Therapeutics Inc. (NASDAQ:LPTX) price on Friday, March 25, fall -2.79% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.74. A look at the stock’s price movement, the close in the last trading session was $1.79, moving within a range at $1.71 and $1.795. The beta value … What Can Leap Therapeutics Inc. (NASDAQ: LPTX) Expect In 2022? Read More »
Leap Therapeutics: Q4 Earnings Insights 2022/03/11 12:50:37 Benzinga
Leap Therapeutics (NASDAQ: LPTX ) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Leap Therapeutics beat estimated earnings by 9.09%, reporting an EPS of … Full story available on Benzinga.com
Leap Therapeutics GAAP EPS of -$0.10 beats by $0.01, revenue of $0.38M beats by $0.08M 2022/03/11 12:33:14 Seeking Alpha
Leap Therapeutics press release (LPTX): Q4 GAAP EPS of -$0.10 beats by $0.01.Revenue of $0.38M (flat Y/Y) beats by $0.08M.CEO comment: "Following our public offering, we are well…
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results 2022/03/11 12:00:00 PR Newswire
CAMBRIDGE, Mass., March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2021. Leap Highlights:…
Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference 2022/03/02 12:00:00 PR Newswire
CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at…